Since VEXAS syndrome in humans is a synthetic and holistic effect of all aspects of mutant hematopoietic cells carrying somatic UBA1 mutations, in the future, it will therefore be required to generate compound Cre lines to test whether a stronger phenotype manifests (i.e., generating Lyz2Cre S100a8CreUba1fl/y). The gene discussed is UBA1; the disease is VEXAS syndrome.